Biotech Values

[jq1234]

Nexavar inhibits the BRAF kinase, as well as other kinases. Is the new drug (PLX4032) a kinase inhibitor?

Yes, PLX4032 is a very selective BRAF kinase inhibitor. Nexavar is mutiple kinase inhibitor including BRAF, which is why it has showed some activity in melanoma. PLX stated that in the past most BRAF inhibitors were not selective enough, too much off-target toxicity, thus couldn't reach high enough dose level to sufficiently inhibit the target.